Intl Fcstone Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 444.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,081 shares of the biopharmaceutical company’s stock after acquiring an additional 45,777 shares during the quarter. Intl Fcstone Inc.’s holdings in Pfizer were worth $1,884,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the period. Franklin Resources Inc. boosted its position in shares of Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after buying an additional 389,629 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after buying an additional 2,028,313 shares during the period. Fisher Asset Management LLC boosted its position in shares of Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the period. Finally, LSV Asset Management boosted its position in shares of Pfizer by 0.6% during the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after buying an additional 199,100 shares during the period. 69.89% of the stock is owned by institutional investors.
PFE has been the subject of several research analyst reports. Jefferies Group set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. BMO Capital Markets restated a “buy” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, September 6th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a research report on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. Pfizer currently has a consensus rating of “Buy” and a consensus target price of $38.77.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share. equities analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 79.01%.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/12/17/pfizer-inc-pfe-holdings-raised-by-intl-fcstone-inc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.